{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Maytenus compound", "anticancer", "mechanisms", "traditional Chinese medicine"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "35116963", "DateRevised": {"Year": "2022", "Month": "05", "Day": "01"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.21037/tcr.2019.09.30"], "Journal": {"ISSN": "2219-6803", "JournalIssue": {"Volume": "8", "Issue": "5", "PubDate": {"Year": "2019", "Month": "Sep"}}, "Title": "Translational cancer research", "ISOAbbreviation": "Transl Cancer Res"}, "ArticleTitle": "Anticancer effect of the traditional Chinese medicine herb Maytenus compound via the EGFR/PI3K/AKT/GSK3\u03b2 pathway.", "Pagination": {"StartPage": "2130", "EndPage": "2140", "MedlinePgn": "2130-2140"}, "Abstract": {"AbstractText": ["Cancer is a leading cause of death worldwide; folk anticancer medicinal plants have applied for cancer treatment. The Maytenus compound tablet as traditional Chinese compound medicine has been approved for alleviating hyperplasia of mammary glands, whether it can inhibit cancer still unknown. The study was to evaluate the anticancer activity of the Maytenus compound tablet.", "MTS assay evaluated the anti-proliferation effect of the Maytenus compound on H226, A2058, 786O and HeLa cancer cells and two normal epithelial cell lines, namely, 16HBE and Hecate. Nude mouse xenograft tumor model using H226 and HeLa cells examined the drug's anticancer effect <i>in vivo</i>. Western blot assay studied the possible mechanism.", "The Maytenus compound indicated obvious ability to against proliferation in four strains of cancer cells, particularly against H226 cells by an IC50 of 85.47\u00b110.06 \u00b5g/mL and against HeLa cells by an IC50 of 128.74\u00b117.46 \u00b5g/mL. However, it had a low cytotoxicity in human normal epithelial cell lines 16HBE with an IC50 of 4,555.86\u00b125.21 \u00b5g/mL and Hecate with an IC50 of 833.56\u00b1181.88 \u00b5g/mL. The Maytenus compound at the 2.45 g/kg oral dosages inhibited the proliferation of H226 cells and HeLa cells in nude mouse with inhibitory rates of 36.06% and 26.45%, respectively, and no organ toxicity. The Maytenus compound could significantly downregulate the expression of pEGFR, pPI3K, pAKT, pGSK3\u03b2, \u03b2-catenin, and c-MYC and upregulate the protein expression of GSK3\u03b2.", "The Maytenus compound has significant anticancer activities against human cancer H226 and HeLa cells both <i>in vitro</i> and <i>in vivo</i>, highlighting it may be an anticancer medicine."], "CopyrightInformation": "2019 Translational Cancer Research. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}, {"Identifier": [], "Affiliation": "Department of Yunnan Tumor Research Institute, the Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China."}], "LastName": "Zeng", "ForeName": "Baozhen", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Ge", "ForeName": "Chunlei", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Zhao", "ForeName": "Wentao", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Traditional medicine research laboratory, Puer Traditional Ethnomedicine Institute, Puer 665000, China."}], "LastName": "Fu", "ForeName": "Kaicong", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Traditional medicine research laboratory, Puer Traditional Ethnomedicine Institute, Puer 665000, China."}], "LastName": "Liu", "ForeName": "Lin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology Yan'An Hospital of Kunming City, Kunming 650118, China."}], "LastName": "Lin", "ForeName": "Zhuying", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Fu", "ForeName": "Qiaofen", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Li", "ForeName": "Zhen", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Li", "ForeName": "Ruilei", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology Yan'An Hospital of Kunming City, Kunming 650118, China."}], "LastName": "Guo", "ForeName": "Huan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}, {"Identifier": [], "Affiliation": "Department of Yunnan Tumor Research Institute, the Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China."}], "LastName": "Li", "ForeName": "Chunyan", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Zhao", "ForeName": "Liufang", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}], "LastName": "Hu", "ForeName": "Hongyan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Traditional medicine research laboratory, Puer Traditional Ethnomedicine Institute, Puer 665000, China."}], "LastName": "Yang", "ForeName": "Hanyu", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anatomy, Guangdong Provincial Key Laboratory of Medical Biomechanics, School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China."}], "LastName": "Huang", "ForeName": "Wenhua", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Yunnan Tumor Research Institute, the Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China."}], "LastName": "Huang", "ForeName": "Youguang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China."}, {"Identifier": [], "Affiliation": "Department of Yunnan Tumor Research Institute, the Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China."}], "LastName": "Song", "ForeName": "Xin", "Initials": "X"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Transl Cancer Res", "NlmUniqueID": "101585958", "ISSNLinking": "2218-676X"}, "CoiStatement": "Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.09.30). The authors have no conflicts of interest to declare."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442", "ArticleIdList": ["10.3322/caac.21442", "29313949"]}, {"Citation": "Khan MA, Ali R, Parveen R, et al. Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from Boswellia serrata. J Ethnopharmacol 2016;191:315-23. 10.1016/j.jep.2016.06.053", "ArticleIdList": ["10.1016/j.jep.2016.06.053", "27346540"]}, {"Citation": "Cipriani TR, Mellinger CG, de Souza LM, et al. A polysaccharide from a tea (infusion) of Maytenus ilicifolia leaves with anti-ulcer protective effects. J Nat Prod 2006;69:1018-21. 10.1021/np060045z", "ArticleIdList": ["10.1021/np060045z", "16872136"]}, {"Citation": "Leite JP, Rastrelli L, Romussi G, et al. Isolation and HPLC quantitative analysis of flavonoid glycosides from Brazilian beverages (Maytenus ilicifolia and M. aquifolium). J Agric Food Chem 2001;49:3796-801. 10.1021/jf010294n", "ArticleIdList": ["10.1021/jf010294n", "11513669"]}, {"Citation": "Momtaz S, Hussein AA, Ostad SN, et al. Growth inhibition and induction of apoptosis in human cancerous HeLa cells by Maytenus procumbens. Food Chem Toxicol 2013;51:38-45. 10.1016/j.fct.2012.09.005", "ArticleIdList": ["10.1016/j.fct.2012.09.005", "22989702"]}, {"Citation": "Ara\u00fajo J\u00fanior RF, Oliveira AL, Pessoa JB, et al. Maytenus ilicifolia dry extract protects normal cells, induces apoptosis and regulates Bcl-2 in human cancer cells. Exp Biol Med (Maywood) 2013;238:1251-8. 10.1177/1535370213494563", "ArticleIdList": ["10.1177/1535370213494563", "23828591"]}, {"Citation": "Kupchan SM, Komoda Y, Court WA, et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972;94:1354-6. 10.1021/ja00759a054", "ArticleIdList": ["10.1021/ja00759a054", "5062169"]}, {"Citation": "Remillard S, Rebhun LI, Howie GA, et al. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975;189:1002-5. 10.1126/science.1241159", "ArticleIdList": ["10.1126/science.1241159", "1241159"]}, {"Citation": "Boyraz B, Sendur MA, Aksoy S, et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 2013;29:405-14. 10.1185/03007995.2013.775113", "ArticleIdList": ["10.1185/03007995.2013.775113", "23402224"]}, {"Citation": "Su J, Zhao P, Kong L, et al. Trichothecin induces cell death in NF-kappaB constitutively activated human cancer cells via inhibition of IKKbeta phosphorylation. PLoS One 2013;8:e71333. 10.1371/journal.pone.0071333", "ArticleIdList": ["10.1371/journal.pone.0071333", "PMC3731298", "23936501"]}, {"Citation": "Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006;5:2676-84. 10.1158/1535-7163.MCT-06-0166", "ArticleIdList": ["10.1158/1535-7163.MCT-06-0166", "17121914"]}, {"Citation": "Tu X, Deng Y, Chen J, et al. Screening study on the anti-angiogenic effects of Traditional Chinese Medicine - Part I: Heat-clearing and detoxicating TCM. J Ethnopharmacol 2016;194:280-7. 10.1016/j.jep.2016.09.010", "ArticleIdList": ["10.1016/j.jep.2016.09.010", "27616026"]}, {"Citation": "Xu Y, Chen X, Chen X, et al. San Huang Decoction downregulates Aurora kinase A to inhibit breast cancer cell growth and enhance chemosenstivity to anti-tumor drugs. Pathol Res Pract 2016;212:696-703. 10.1016/j.prp.2016.05.004", "ArticleIdList": ["10.1016/j.prp.2016.05.004", "27461831"]}, {"Citation": "Qu C, Ma J, Liu X, et al. Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells. Front Cell Neurosci 2017;11:310. 10.3389/fncel.2017.00310", "ArticleIdList": ["10.3389/fncel.2017.00310", "PMC5626852", "29033794"]}, {"Citation": "Cele ND, Sangweni NF, Mosa RA, et al. Testicular Dysfunction Ameliorative Effect of the Methanolic Roots Extracts of Maytenus procumbens and Ozoroa paniculosa. Evid Based Complement Alternat Med 2017;2017:8204816. 10.1155/2017/8204816", "ArticleIdList": ["10.1155/2017/8204816", "PMC5734007", "29348775"]}, {"Citation": "Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. 10.3322/caac.21262", "ArticleIdList": ["10.3322/caac.21262", "25651787"]}, {"Citation": "Wright TC, Jr, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol 2012;26:197-208. 10.1016/j.bpobgyn.2011.11.004", "ArticleIdList": ["10.1016/j.bpobgyn.2011.11.004", "22385539"]}, {"Citation": "Yousef BA, Hassan HM, Zhang LY, et al. Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review. Curr Cancer Drug Targets 2017;17:100-8. 10.2174/1568009616666160112105824", "ArticleIdList": ["10.2174/1568009616666160112105824", "26758533"]}, {"Citation": "Shabbir M, Syed DN, Lall RK, et al. Potent anti-proliferative, pro-apoptotic activity of the Maytenus royleanus extract against prostate cancer cells: evidence in in-vitro and in-vivo models. PLoS One 2015;10:e0119859. 10.1371/journal.pone.0119859", "ArticleIdList": ["10.1371/journal.pone.0119859", "PMC4370495", "25798940"]}, {"Citation": "Yamashita-Kashima Y, Shu S, Harada N, et al. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. Oncol Rep 2013;30:1087-93. 10.3892/or.2013.2547", "ArticleIdList": ["10.3892/or.2013.2547", "23783223"]}, {"Citation": "Park IK, Hyun K, Kim ER, et al. The prognostic effect of the epidermal growth factor receptor gene mutation on recurrence dynamics of lung adenocarcinoma. Eur J Cardiothorac Surg 2018;54:1022-7. 10.1093/ejcts/ezy220", "ArticleIdList": ["10.1093/ejcts/ezy220", "29878144"]}, {"Citation": "Wei H, Zhu Z, Lu L. Inhibition of EGFR nuclear shuttling decreases irradiation resistance in HeLa cells. Folia Histochem Cytobiol 2017;55:43-51. 10.5603/FHC.a2017.0007", "ArticleIdList": ["10.5603/FHC.a2017.0007", "28518211"]}, {"Citation": "Hosur V, Farley ML, Burzenski LM, et al. ADAM17 is essential for ectodomain shedding of the EGF-receptor ligand amphiregulin. FEBS Open Bio 2018;8:702-10. 10.1002/2211-5463.12407", "ArticleIdList": ["10.1002/2211-5463.12407", "PMC5881543", "29632822"]}, {"Citation": "Masroor M, Mir R, Javid J, et al. Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases. Asian Pac J Cancer Prev 2015;16:6445-9. 10.7314/APJCP.2015.16.15.6445", "ArticleIdList": ["10.7314/APJCP.2015.16.15.6445", "26434857"]}, {"Citation": "Xu L, Qu X, Li H, et al. Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis in gastric cancer cells. Oncol Rep 2014;32:318-24. 10.3892/or.2014.3183", "ArticleIdList": ["10.3892/or.2014.3183", "24840271"]}, {"Citation": "Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015;16:830-8. 10.1016/S1470-2045(15)00026-1", "ArticleIdList": ["10.1016/S1470-2045(15)00026-1", "26051236"]}, {"Citation": "Nogueira-Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer 2014;120:1187-93. 10.1002/cncr.28471", "ArticleIdList": ["10.1002/cncr.28471", "24615735"]}, {"Citation": "Gao Y, Yu H, Liu Y, et al. Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis. Cell Physiol Biochem 2018;45:131-47. 10.1159/000486253", "ArticleIdList": ["10.1159/000486253", "29310118"]}, {"Citation": "Liu Q, Liang X, Niu C, et al. Ellagic acid promotes A549 cell apoptosis via regulating the phosphoinositide 3-kinase/protein kinase B pathway. Exp Ther Med 2018;16:347-52.", "ArticleIdList": ["PMC5995078", "29896260"]}, {"Citation": "Ni J, Peng Y, Yang FL, et al. Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer. Onco Targets Ther 2018;11:3303-12. 10.2147/OTT.S161311", "ArticleIdList": ["10.2147/OTT.S161311", "PMC5993038", "29892197"]}, {"Citation": "Zhao W, Sun Q, Yu Z, et al. MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. Gene 2018;670:31-7. 10.1016/j.gene.2018.05.100", "ArticleIdList": ["10.1016/j.gene.2018.05.100", "29803922"]}, {"Citation": "Chin YR, Yuan X, Balk SP, et al. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov 2014;4:942-55. 10.1158/2159-8290.CD-13-0873", "ArticleIdList": ["10.1158/2159-8290.CD-13-0873", "PMC4125464", "24838891"]}, {"Citation": "Vivanco I, Chen ZC, Tanos B, et al. A kinase-independent function of AKT promotes cancer cell survival. Elife 2014. doi: .10.7554/eLife.03751", "ArticleIdList": ["10.7554/eLife.03751", "PMC4337624", "25551293"]}, {"Citation": "Tang Q, Zheng X, Zhang J. Long non-coding RNA CRNDE promotes heptaocellular carcinoma cell proliferation by regulating PI3K/Akt /beta-catenin signaling. Biomed Pharmacother 2018;103:1187-93. 10.1016/j.biopha.2018.04.128", "ArticleIdList": ["10.1016/j.biopha.2018.04.128", "29864897"]}, {"Citation": "Shu T, Liu C, Pang M, et al. Salvianolic acid B promotes neural differentiation of induced pluripotent stem cells via PI3K/AKT/GSK3beta/beta-catenin pathway. Neurosci Lett 2018;671:154-60. 10.1016/j.neulet.2018.02.007", "ArticleIdList": ["10.1016/j.neulet.2018.02.007", "29421539"]}, {"Citation": "Song Z, Han X, Shen L, et al. PTEN silencing enhances neuronal proliferation and differentiation by activating PI3K/Akt/GSK3beta pathway in vitro. Exp Cell Res 2018;363:179-87. 10.1016/j.yexcr.2018.01.001", "ArticleIdList": ["10.1016/j.yexcr.2018.01.001", "29305963"]}, {"Citation": "Hu W, Xiao L, Cao C, et al. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3beta/beta-catenin pathway. Oncotarget 2016;7:15161-72.", "ArticleIdList": ["PMC4924777", "26943030"]}, {"Citation": "Lv J, Wei Y, Chen Y, et al. Dexmedetomidine attenuates propofol-induce neuroapoptosis partly via the activation of the PI3k/Akt/GSK3beta pathway in the hippocampus of neonatal rats. Environ Toxicol Pharmacol 2017;52:121-8. 10.1016/j.etap.2017.03.017", "ArticleIdList": ["10.1016/j.etap.2017.03.017", "28411582"]}, {"Citation": "Lee SK, Hwang JH, Choi KY. Interaction of the Wnt/beta-catenin and RAS-ERK pathways involving co-stabilization of both beta-catenin and RAS plays important roles in the colorectal tumorigenesis. Adv Biol Regul 2018;68:46-54. 10.1016/j.jbior.2018.01.001", "ArticleIdList": ["10.1016/j.jbior.2018.01.001", "29449169"]}, {"Citation": "Meffre D, Grenier J, Bernard S, et al. Wnt and lithium: a common destiny in the therapy of nervous system pathologies? Cell Mol Life Sci 2014;71:1123-48. 10.1007/s00018-013-1378-1", "ArticleIdList": ["10.1007/s00018-013-1378-1", "23749084"]}, {"Citation": "Deng X, Hamamoto R, Vougiouklakis T, et al. Critical roles of SMYD2-mediated beta-catenin methylation for nuclear translocation and activation of Wnt signaling. Oncotarget 2017;8:55837-47. 10.18632/oncotarget.19646", "ArticleIdList": ["10.18632/oncotarget.19646", "PMC5593527", "28915556"]}, {"Citation": "Xu H, Zhao X, Liu X, et al. Antitumor effects of traditional Chinese medicine targeting the cellular apoptotic pathway. Drug Des Devel Ther 2015;9:2735-44.", "ArticleIdList": ["PMC4445699", "26056434"]}, {"Citation": "Chen Y, Wu H, Wang X, et al. Huaier Granule extract inhibit the proliferation and metastasis of lung cancer cells through down-regulation of MTDH, JAK2/STAT3 and MAPK signaling pathways. Biomed Pharmacother 2018;101:311-21. 10.1016/j.biopha.2018.02.028", "ArticleIdList": ["10.1016/j.biopha.2018.02.028", "29499405"]}, {"Citation": "Taplin S, Vashisht K, Walles M, et al. Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings. J Appl Toxicol 2018;38:600-15. 10.1002/jat.3582", "ArticleIdList": ["10.1002/jat.3582", "29388692"]}]}], "History": [{"Year": "2019", "Month": "2", "Day": "18"}, {"Year": "2019", "Month": "8", "Day": "28"}, {"Year": "2022", "Month": "2", "Day": "4", "Hour": "5", "Minute": "50"}, {"Year": "2019", "Month": "9", "Day": "1", "Hour": "0", "Minute": "0"}, {"Year": "2019", "Month": "9", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "2019", "Month": "9", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35116963", "PMC8798896", "10.21037/tcr.2019.09.30", "tcr-08-05-2130"]}}]}